DE Vulder SRL
1.0 FTEThe score of DE Vulder shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity 0 % Total assets -9 % Headcount (avg FTE) 0 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
DE Vulder's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | 58,208 € | ||||
| Equity | 78,437 € | ||||
| Cash | 102,332 € | ||||
| EBITDA | 115,741 € | ||||
| Total assets | 887,085 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 19 Jun 2026
- Year ended 31 Dec 2024filed on 20 Jun 2025
- Year ended 31 Dec 2023filed on 29 Aug 2024
- Year ended 31 Dec 2022filed on 25 Jul 2023
- Year ended 31 Dec 2021filed on 29 Aug 2022
DE Vulder's financial analysis
- Solvency8.8%sector median: 44.2%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of DE Vulder
DE Vulder's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0811.979.773
- VAT number
- BE0811979773
- Peppol
- Registered · 0208:0811979773 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 29 May 2009
- Registered office
- 1761 Roosdaal
- Size
- Micro · 1.0 FTE
- Latest accounts
- 2025 · filed on 19 Jun 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
DE Vulder (SRL) has been based in Roosdaal since 2009, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 58,208 € and equity of 78,437 €; its revenue is not published. With 1.0 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 8.8%, below the median of its sector (44.2%).
Companies similar to DE Vulder
Companies in the same business, of comparable size and area, outside its group.
- Pharmacie Alleur Retail sale of pharmaceutical products Ans · balance sheet 887,668 €
- Apotheek Vandeputte Pharmacie Retail sale of pharmaceutical products Spiere-Helkijn · balance sheet 888,451 €
- Phinn Retail sale of pharmaceutical products Buggenhout · balance sheet 885,031 €
- Cobra Apotheek Rosselaar Retail sale of pharmaceutical products Mol · balance sheet 884,462 €
- Pharma-Thim Retail sale of pharmaceutical products Genappe · balance sheet 883,008 €
- Apoteek Dreezen Retail sale of pharmaceutical products Hasselt · balance sheet 882,214 €
- Pharmavrai Retail sale of pharmaceutical products Huy · balance sheet 880,268 €
- Pharmaplus Grand Place Retail sale of pharmaceutical products Tournai · balance sheet 896,066 €
Frequently asked questions about DE Vulder
What is the revenue of DE Vulder?
DE Vulder files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of DE Vulder?
In Belgium, the VAT number is the company number prefixed with BE: BE0811979773 for DE Vulder, if the company is VAT-registered. Its company number (CBE) is 0811.979.773.
Where is the registered office of DE Vulder?
According to the CBE register, the registered office of DE Vulder is in 1761 Roosdaal.
What is the equity of DE Vulder?
At the close of the 2025 financial year, the equity of DE Vulder amounts to 78,437 €, a solvency of 8.8% of total assets.
How many people work at DE Vulder?
1.0 full-time equivalents on average according to the 2025 social balance sheet.
Who manages DE Vulder?
The register lists 2 active mandates at DE Vulder. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of DE Vulder
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →